Detalhe da pesquisa
1.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood
; 141(15): 1817-1830, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706355
2.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 23(2): 279-291, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35033226
3.
Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities.
Cell Genom
; 4(1): 100444, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190106
4.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Cancer Cell
; 42(1): 35-51.e8, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134936
5.
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Clin Cancer Res
; 30(8): 1655-1668, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277235
6.
Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA.
Nat Protoc
; 18(8): 2404-2414, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37391666
7.
Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies.
Cancer Immunol Res
; 10(7): 788-799, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605261
8.
The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability.
J Virol
; 83(17): 8885-92, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19553310